Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. Additionally we are shipping and many more products for this protein.
Showing 10 out of 75 products:
Human Polyclonal LATS1 Primary Antibody for IHC (p), WB - ABIN391033
Iida, Hirota, Morisaki, Marumoto, Hara, Kuninaka, Honda, Kosai, Kawasuji, Pallas, Saya: Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function. in Oncogene 2004
Show all 6 references for ABIN391033
Human Polyclonal LATS1 Primary Antibody for WB - ABIN2787626
Zhang, Smolen, Haber: Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. in Cancer research 2008
Human Polyclonal LATS1 Primary Antibody for IF (p), IHC (p) - ABIN872292
Grijalva, Huizenga, Mueller, Rodriguez, Brazzo, Camargo, Sadri-Vakili, Vakili: Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. in American journal of physiology. Gastrointestinal and liver physiology 2014
Human Polyclonal LATS1 Primary Antibody for EIA, IHC (p) - ABIN359091
Eiring, Neviani, Santhanam, Oaks, Chang, Notari, Willis, Gambacorti-Passerini, Volinia, Marcucci, Caligiuri, Leone, Perrotti: Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. in Blood 2008
Thus AMOT (show AMOT Antibodies) is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis.
lats genes show distinctly different expression profiles during gastrulation. lats1 is almost ubiquitously expressed through development, and lats2 (show LATS2 Antibodies) is more prominently expressed in the non-neural ectoderm region of zebrafish gastrula.
Results showed that the Hippo pathway is active in ovarian follicles and that LATS1 is required to maintain the pool of germ cells and primordial follicles.
The control of LATS activation by angiotensin II and subsequent YAP (show YAP1 Antibodies) localization is important for podocyte homeostasis and survival.
Willin (show FRMD6 Antibodies) is predominantly expressed in fibroblasts and that Willin (show FRMD6 Antibodies) expression activates the Hippo signaling cascade
LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization.
KIBRA (show WWC1 Antibodies) associates with and activates Lats (large tumor suppressor) 1 and 2 kinases by stimulating their phosphorylation on the hydrophobic motif
Lats1 enhances the activity of FOXl2 (show FOXL2 Antibodies) as a repressor of the StAr promoter. st
Overexpression of YAP2 (show YAP1 Antibodies) in cells promoted apoptosis, whereas the Mst2 (show STK3 Antibodies)/Lats1-induced phosphorylation of YAP (show YAP1 Antibodies) partially rescued the cells from apoptotic death.
Genome-wide location arrays in cell lines of various cell types revealed that Lats1 was a transcriptional target of CUX1 (show CUX1 Antibodies).
PARD3 (show PARD3 Antibodies) promotes interaction between PP1A (show PPP1CA Antibodies) and LATS1 to induce LATS1 dephosphorylation and inactivation,leading to dephosphorylation and activation of TAZ (show TAZ Antibodies)
Loss of LATS1 expression is associated with breast neoplasms.
Phosphorylation of CHO1 (show KIF23 Antibodies) at S716 by Lats1 regulate its centrosomal localization, and that phosphorylated CHO1 (show KIF23 Antibodies) interacts with and activates LIMK1 (show LIMK1 Antibodies) during early mitosis.
LATS1 phosphorylates the Thr7 residue of the APC (show APC Antibodies)/C component CDC26 (show CDC26 Antibodies) directly
These results demonstrated that as an inhibitor of YAP (show YAP1 Antibodies), LATS1 was decreased via downregulation of YAP (show YAP1 Antibodies) using RNAi. This therefore indicated that the change in YAP (show YAP1 Antibodies) levels in hepatocellular carcinoma cells may regulate LATS1 in a feedback manner.
LATS1 promoter hypermethylation is associated with oral squamous cell carcinomas.
results reported here further support that LATS1/2 act normally as tumor suppressors and loss of their functions contributes to human cancer development
Phosphorylation of S716 NDR (show STK38 Antibodies)/LATS, present only in the longest Kif23 (show KIF23 Antibodies) isoform, is required for phosphorylation at S814, revealing phosphorylation at these two sites, and differential regulation of Kif23 (show KIF23 Antibodies)-14-3-3 (show YWHAQ Antibodies) interaction for the two Kif23 (show KIF23 Antibodies) isoforms.
Findings suggest that polyomavirus middle T-antigen (PyMT) activates the Hippo pathway tumor suppressor Lats in a Src (show SRC Antibodies)-dependent manner.
LATS1 and LATS2 (show LATS2 Antibodies) kinases play an important role in the regulation of NS5A function through site-specific post-translational modification and that phosphorylation of Ser (show SIGLEC1 Antibodies)/Thr71 is essential for optimal viral genome replication.
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.
large tumor suppressor
, serine/threonine-protein kinase LATS1
, LATS homolog 1
, LATS, large tumor suppressor, homolog 1
, LATS, large tumor suppressor, homolog 1 (Drosophila)
, serine/threonine-protein kinase LATS1-like
, WARTS protein kinase
, large tumor suppressor homolog 1
, large tumor supressor, homolog 1
, LATS (large tumor suppressor, Drosophila) homolog 1
, large tumor suppressor 1